World Computer Aided Detection (CAD) Industry

  • January 2015
  • -
  • Global Industry Analysts
  • -
  • 115 pages

This report analyzes the US and European markets for Computer Aided Detection (CAD) in US$ Thousands by the following Application Segments - Breast, Chest, and Others. The US market is also analysed in Number of Units for the above Application Segments. The report also provides a consolidated, single-segment volume analysis for the European market. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 29 companies including many key and niche players such as -

EDDA Technology, Inc.
Hologic, Inc.
iCAD, Inc.
Invivo Corp.
Merge Healthcare, Inc.

Table Of Contents

World Computer Aided Detection (CAD) Industry



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. A US AND EUROPEAN MARKET REPORT

1. OUTLOOK II-1
Computer Aided Detection - Offering “Second Look” for
Radiology Analysis II-1
The Need for Early Disease Diagnosis and the Role of CAD II-1
Table 1: Global Aging Population by Age Group: 1975-2050
(includes corresponding Graph/Chart) II-2
Market Highlights II-3
Major Drivers and Restraints II-3
Breast CAD to Hold its Forte in the CAD Market II-4
Recession in Retrospect and the Road Ahead II-5
Improving Healthcare Expenditure to Foster Growth II-5
Table 2: Per-Capita Healthcare Expenditure in US$ for Select
Regions: 2014 (includes corresponding Graph/Chart) II-6

Table 3: Healthcare Spending as a Percentage of GDP in Select
Developing Countries (2014E) (includes corresponding
Graph/Chart) II-6

Table 4: Healthcare Spending as a Percentage of GDP in Select
Developed Countries for 2004, 2008 and 2014E (includes
corresponding Graph/Chart) II-6

Table 5: Top 20 Countries with the Highest Healthcare
Spending as a Percentage of GDP: 2014E (includes
corresponding Graph/Chart) II-7

2. MARKET OVERVIEW and TRENDS II-8
From “Second Reader” to “First Reader” Use - the Unconquered
Avenue of CAD Systems II-8
CAD Use Rises despite Controversies II-8
Replacements to Fuel Market Growth II-9
High Dependence on Related Modality Continues II-9
Market Calls for Higher Efficiencies in CAD II-9
Product Developments Underway to Expand Utility II-9
Information Provision - A Key Feature under Development for
Enhanced Efficiency II-10
Research finds Interactive Use of CAD More Efficient II-11
Rising Incidence of Cancer - A Major Market Driver II-11
Cancer Prone Sites based on Age II-11
World Cancer Statistics - Incidence and Mortality Data II-12
Table 6: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported in
Thousands for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-12

Table 7: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer- Related Deaths in Thousands
for Asia-Oceania, Europe, North America, Latin America and the
Caribbean, and Africa (includes corresponding Graph/Chart) II-13

Table 8: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung and
Bronchus, Prostate, Colorectal and Liver Cancers (includes
corresponding Graph/Chart) II-13

Table 9: Global Incidence of Common Cancers in Women (2012):
Number of New Cases Reported in Thousands for Breast,
Colorectal, Lung and Bronchus and Liver Cancers (includes
corresponding Graph/Chart) II-14

Table 10: Global Cancer Mortality in Men for Select Cancers
(2012): Number of Deaths in Thousands for Lung and Bronchus,
Liver, Colorectal and Prostate Cancers (includes
corresponding Graph/Chart) II-14

Table 11: Global Cancer Mortality in Women for Select
Cancers (2012): Number of Deaths in Thousands for Breast,
Lung and Bronchus, Colorectal and Liver (includes
corresponding Graph/Chart) II-14

Table 12: World Breast Cancer Statistics (2012): Top 20
Countries with Highest Breast Cancer Rates (includes
corresponding Graph/Chart) II-15

3. COMPETITION II-16
iCAD - A Leading Independent Player in the Mammography CAD
Segment II-16

4. APPLICATIONS OF CAD II-17
Present Applications of CAD II-17
What Lies Ahead at the Application Front? II-17
CAD in Breast Cancer II-17
CAD Simplifies Breast MRI Image Analysis; Tremendous Scope
for Adoption Ahead II-17
Breast MRI - Lagging behind Mammography in Cancer Detection II-18
CAD Solutions for Breast Cancer II-18
SecondLook Digital (iCAD) II-18
R2 ImageChecker (Hologic, Inc.) II-18
SpectraLook CAD Solution (iCAD) II-18
DynaCAD Breast (Invivo) II-19
CADstream Breast MRI Application (Merge Healthcare) II-19
List of Select Approved CAD Solutions for Breast MRI II-19
CAD in Prostate Cancer II-19
CAD in Lung Cancer II-20
The Background II-20
An Overview of CAD Solutions for Lung Cancer Detection II-21
IQQA (EDDA Technology) II-21
ClearRead +Detectâ„¢ (formerly OnGuard) (Riverain Technologies) II-21
xLNA (Philips) II-21
syngo CAD Solutions (Siemens) II-22
CAD in Liver Cancer II-22
CAD Solutions for Liver Cancer Detection II-22
CADstream (Merge Healthcare) II-22
IQQA (EDDA Technology) II-22
CAD in the Detection of Prostate Cancer II-22
Available CAD Solutions for Prostate Cancer II-23
CAD in the Detection of Colon Cancer II-23
CAD in Cardiology II-24
Increasing Need for CAD in Cardiology II-24
Table 13: Cardiovascular Disease Incidence in the US by
Gender and Age Group (per 1,000 Adults) (includes
corresponding Graph/Chart) II-24
Automatic Workflow Integration Fuels Demand for Cardiac CAD II-24
Significant Hurdles Exist for CAD in Cardiology II-25

5. REGIONAL PERSPECTIVE II-26

5a. THE UNITED STATES II-26
A.Market Analysis II-26
Current and Future Analysis II-26
Challenges in Evaluation Dents Approvals of New CAD Systems II-26
Final Guidance Documents on CAD offers Respite to Industry
Players II-27
CAD Devices, as Defined by the FDA II-27
Guidance on 510(k) Application II-28
FDA's FFDM Reclassification to Benefit CAD Market II-28
Competition II-28
Table 14: The US Mammography CAD Market by Leading Player:
2014 (includes corresponding Graph/Chart) II-28
Select FDA Approved CAD Software: 2001-2013 II-29
Ageing Demographics: A Key Market Driver II-29
Table 15: North American Elderly Population by Age Group:
1975-2050 (includes corresponding Graph/Chart) II-30
Rising Cancer Incidence, and the Need for Early Detection
Propel Market Growth II-30
Table 16: New Cancer Cases in the US by State: 2014 II-31

Table 17: New Cancer Cases in the US by Gender and Affected
Site: 2014 II-33

Table 18: Cancer Related Deaths in the US by Gender and
Body Site: 2014 II-35

Table 19: Cancer Mortality in the US by Site for Male and
Female Populations (2013): Breakdown of Number of Deaths
for Breast, Lung and Bronchus, Colon and Rectum, Liver and Bile
Duct, Prostate and Other Cancers (includes corresponding
Graph/Chart) II-37
CAD to Gain from Rapid Growth in CTC Volumes II-37
Physicians' Reluctance to Follow USPSTF - A Shot in the Arm
for CAD Manufacturers II-38
Mammography and Breast MRI, and CAD Reimbursement in the US II-38
CMS Coverage for Screening and Diagnostic Mammography and
Breast MRI - A Review II-38
Table 20: Medicare Reimbursement Codes and Allowable Rates
for CAD in Mammography: 2012-2014 II-39
Low and Spotty Reimbursement Mars CAD in Prostate Cancer
Detection II-39
No Separate Codes for CAD in Prostate MRI II-39
B.Market Analytics II-40
Value Analytics II-40
Table 21: The US Recent Past, Current and Future Analysis for
Computer Aided Detection (CAD) by Application - Breast,
Chest and Other CAD Markets Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2013 through
2020 (includes corresponding Graph/Chart) II-40

Table 22: The US Historic Review for Computer Aided
Detection (CAD) by Application - Breast, Chest and Other
CAD Markets Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2007 through 2012
(includes corresponding Graph/Chart) II-41

Table 23: The US 14-Year Perspective for Computer Aided
Detection (CAD) by Application - Percentage Breakdown of
Dollar Sales for Breast, Chest and Other CAD Markets for
Years 2007, 2014 and 2020 (includes corresponding
Graph/Chart) II-42
Volume Analytics II-43
Table 24: The US Recent Past, Current and Future Analysis for
Computer Aided Detection (CAD) by Application - Breast,
Chest and Other CAD Markets Independently Analyzed with
Annual Sales Figures in Units for Years 2013 through 2020
(includes corresponding Graph/Chart) II-43

Table 25: The US Historic Review for Computer Aided
Detection (CAD) by Application - Breast, Chest and Other
CAD Markets Independently Analyzed with Annual Sales
Figures in Units for Years 2007 through 2012 (includes
corresponding Graph/Chart) II-44

Table 26: The US 14-Year Perspective for Computer Aided
Detection (CAD) by Application - Percentage Breakdown of
Unit Sales for Breast, Chest and Other CAD Markets for
Years 2007, 2014 and 2020 (includes corresponding
Graph/Chart) II-45

5b. EUROPE II-46
A.Market Analysis II-46
Economic Woes Dampen European CAD Market Prospects II-46
Long-Term Prospects Appear Brighter II-46
Breast CAD Dominates, Other Applications to Witness Fastest
Growth II-46
Rising Incidence of Cancer II-47
Table 27: European Cancer Incidence by Geographic Region
(2012): Number of New Cancer Cases Reported in Thousands
for Western Europe, Northern Europe, Southern Europe, and
Central and Eastern Europe (includes corresponding
Graph/Chart) II-48

Table 28: Cancer Incidence in Western Europe by Site
(2012): Number of New Cancer Cases Reported in Thousands
for Prostate, Breast, Colorectal, Lung and Other Cancers
(includes corresponding Graph/Chart) II-48

Table 29: Cancer Incidence in Northern Europe by Site
(2012): Number of New Cancer Cases Reported in Thousands
for Breast, Prostate, Colorectal, Lung and Other Cancers
(includes corresponding Graph/Chart) II-49

Table 30: Cancer Incidence in Southern Europe by Site
(2012): Number of New Cancer Cases Reported in Thousands
for Colorectal, Breast, Lung, Prostate and Other Cancers
(includes corresponding Graph/Chart) II-49

Table 31: Cancer Incidence in Central and Eastern Europe by
Site (2012): Number of New Cancer Cases Reported in
Thousands for Lung, Colorectal, Breast, Stomach and Other
Cancers (includes corresponding Graph/Chart) II-49
Ageing Population Boosts Demand for Computer Aided Detection II-50
Table 32: European Country-wise Statistics of 60+
Population as % of Total Population: 2013 (includes
corresponding Graph/Chart) II-50
B.Market Analytics II-51
Value Analytics II-51
Table 33: European Recent Past, Current and Future Analysis
for Computer Aided Detection (CAD) by Application - Breast,
Chest and Other CAD Markets Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2013 through
2020 (includes corresponding Graph/Chart) II-51

Table 34: European Historic Review for Computer Aided
Detection (CAD) by Application - Breast, Chest and Other
CAD Markets Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2007 through 2012
(includes corresponding Graph/Chart) II-52

Table 35: European 14-Year Perspective for Computer Aided
Detection (CAD) by Application - Percentage Breakdown of
Dollar Sales for Breast, Chest and Other CAD Markets for
Years 2007, 2014 and 2020 (includes corresponding
Graph/Chart) II-53
Volume Analytics II-54
Table 36: European Recent Past, Current and Future Analysis
for Computer Aided Detection (CAD) Market Analyzed with
Annual Sales Figures in Units for Years 2013 through 2020
(includes corresponding Graph/Chart) II-54

Table 37: European Historic Review for Computer Aided
Detection (CAD) Market Analyzed with Annual Sales Figures
in Units for Years 2007 through 2012 (includes
corresponding Graph/Chart) II-55

6. PRODUCT OVERVIEW II-56
CAD - An Introduction II-56
A Brief History of CAD II-56
Methodology II-56
Sensitivity / Specificity II-57
Absolute Detection Rate II-57
Applications of Computer-Aided Detection II-57
Breast Cancer II-57
Lung Cancer (Bronchial Carcinoma) II-57
Evolution of Computer-Aided Detection for Mammography II-58
CAD Technology - Working Operation II-58
Existing Limitations of CAD II-59

7. PRODUCT INNOVATIONS/INTRODUCTIONS II-60
VuCOMP Obtains Market Clearance for M-Vu® CAD and M-Vu Breast
Density in Turkey II-60
VuCOMP Receives US FDA Approval for M-Vu CAD for Mammography
Version 3.1 II-60
iCAD Obtains FDA Clearance for Mammography CAD Platform II-60
VuCOMP Receives Premarket Approval from FDA for M-Vu Film
Mammography CAD II-60
iCAD Introduces Advanced Mammography CAD System II-60
Parascript Unveils Updated AccuDetect CAD Technology II-60

8. RECENT INDUSTRY ACTIVITY II-61
iCAD Expands Existing Partnership with Volpara Solutions II-61
Salient Imaging Takes Over Medipattern II-61
Real Time Tomography Inks Licensing Agreement with im3D II-61
iCAD and Invivo Ink Agreement II-61
Planmed and Three Palm Software Ink Partnership Agreement II-61
Sectra Signs Agreement with Merge Healthcare II-61

9. FOCUS ON SELECT PLAYERS II-62
EDDA Technology, Inc. (US) II-62
Hologic, Inc. (US) II-62
iCAD, Inc. (US) II-63
Invivo Corp. (US) II-65
Merge Healthcare, Inc. (US) II-65
Riverain Technologies (US) II-66
Salient Imaging, Inc. (US) II-67
Siemens Healthcare (Germany) II-67
VuCOMP Inc. (US) II-68


III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 29 (including Divisions/Subsidiaries - 31)

The United States (21)
Japan (1)
Europe (8)
- Germany (2)
- Italy (1)
- Spain (1)
- Rest of Europe (4)
Asia-Pacific (Excluding Japan) (1)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • February 2015
  • by Global Data

PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023 Summary Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition ...

PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • March 2015
  • by Global Data

PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which ...

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • February 2015
  • by Global Data

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary The lupus therapeutics market is dominated by generics and ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.